Skip to main content
Harvard Medical School and Lumera to Collaborate on a New Protein Biochip
Microvision owns approximately 4.6 million shares of LMRA. Harvard Medical School and Lumera to Collaborate on a New Protein BiochipBOTHELL, Wash.--(BUSINESS WIRE)--Jan. 9, 2006--Lumera Corporation (NASDAQ:LMRA - News), a leader in the emerging field of nanotechnology, announced today that is has entered into a collaborative agreement with Harvard Medical School (HMS) and the Harvard Institute of Proteomics, a division of HMS. Under the terms of the agreement, Lumera and HMS will develop a next generation silicon chip substrate that combines Lumera's NanoCapture(TM) technology with HMS's NAPPA(TM) methodology (nucleic acid programmable protein arrays). The resultant 10,000-spot very high density protein arrays are expected to significantly increase the speed of drug discovery and life science research.
"The 10,000-spot biochip is a very important step towards our ultimate goal of producing a whole proteome biochip," said Joshua LaBaer, Director of the Harvard Institute of Proteomics. "As we increase spot density, we are able to gather more data about proteins from a single experiment." The new Lumera protein arrays are critical to the bioscience and pharmaceutical markets that need faster methods for drug discovery, biomarker discovery and solving complex problems in systems biology. Using current research methods and materials, array densities of up to about 800 spots are possible. However, with the new, proprietary Lumera array, researchers will be able to analyze high-throughput expression of well over 10,000 discrete proteins, in biologically-active arrays built from available cDNA libraries.
"Professor LaBaer's work on protein arrays at the Harvard Institute of Proteomics has been substantial and we believe is revolutionizing proteomics," said Lumera CEO Tom Mino. "They have shown the NAPPA platform as an extremely useful tool for biomarker discovery in cancer and diabetes, as well as for cutting-edge homeland bio-defense applications. We are very excited to be working with Dr. LaBaer and his team, as this represents a major milestone for Lumera's bioscience technology."
HMS's NAPPA methods provide a simple, cost-effective way to produce, as a single element of a microarray, freshly synthesized protein corresponding to any gene of known sequence. Combined with Lumera's expertise in surface chemistry, the new biochip is expected to increase the sensitivity and throughput of the NAPPA technology by increasing the number of features on the array without sacrificing the amount of protein produced per feature. This avoids the cost and major technical difficulties involved in printing protein arrays one protein at a time.
The Harvard Institute of Proteomics' protein array technology, NAPPA, was first published in the July 2004 issue of the journal, Science. NAPPA starts with a printed cDNA array and generates a self-assembled protein array using a combination of chemistries and biological methods. A cell free expression mix produces proteins from the printed genes. The resulting expression product is immobilized on a surface capture system providing for fresh, easily definable, protein arrays made directly from cDNA libraries, and easily printed with commonly available equipment and methods. The arrays can be stored and easily handled, very much like today's commonly used expression arrays. Protein is produced and captured only when the user is ready to use the array.
Although financial terms were not disclosed, under this agreement, HMS and Lumera will share rights to jointly developed intellectual property.
This blog is the author's personal website. It is not affiliated with MicroVision, Inc. or any company. This website does not recommend the purchase or sale of any stocks, options, bonds or any investment of any kind. This website does not provide investment advice. Disclaimer and Notices: Disclaimer: This website may contain "forward-looking" information including statements concerning the company's outlook for the future, as well as other statements of beliefs, future plans and strategies or anticipated events, and similar expressions concerning matters that are not historical facts. The forward-looking information and statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, the statements. The information on this website includes forward looking statements, including statements regarding projections of future operations, product applications, development and production, future benefits of contractual arrangements, growth in demand, as well as statements containing words like believe, estimate, expect, anticipate, target, plan, will, could, would, and other similar expressions. These statements are not guarantees of future performance. Actual results could differ materially from the results implied or expressed in the forward looking statement. Additional information concerning factors that could cause actual results to differ materially from those in the forward looking statements are included in MVIS most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission under the heading 'Risk factors related to the company's business,' and our other reports filed with the Comission from time to time. Except as expressly required by Federal securities laws, MVIS Blog undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events, changes in circumstances, or other reasons. Legal Notice: Although considerable care has been taken in preparing and maintaining the information and material contained on this website, MVIS Blog makes no representation nor gives any warranty as to the currency, completeness, accuracy or correctness of any of the elements contained herein. Facts and information contained in the website are believed to be accurate at the time of posting. However, information may be superseded by subsequent disclosure, and changes may be made at any time without prior notice. MVIS Blog shall not be responsible for, or liable in respect of, any damage, direct or indirect, or of any nature whatsoever, resulting from the use of the information contained herein. While the information contained herein has been obtained from sources believed to be reliable, its accuracy and completeness cannot be guaranteed. MVIS Blog has not independently verified the facts, assumptions, and estimates contained on this website. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, or completeness of the information and opinions contained on this website. Consequently, MVIS Blog assumes no liability for the accompanying information, which is being provided to you solely for evaluation and general information. This website does not contain inside information, proprietary or confidential information learned or disclosed as part of employment relationships or under nondisclosure agreements or otherwise.
Comments
Post a Comment